qRT-PCR平台和CellSearch系统检测肝细胞肝癌患者循环肿瘤细胞性能比较

doi:10.3969/j.issn.1673-8640.2019.10.014

检验医学 ›› 2019, Vol. 34 ›› Issue (10): 927-931.DOI: 10.3969/j.issn.1673-8640.2019.10.014

• 技术研究与评价·论著 • 上一篇下一篇

qRT-PCR平台和CellSearch系统检测肝细胞肝癌患者循环肿瘤细胞性能比较

曹旻璐, 沈敏娜, 周琰, 王蓓丽, 张春燕, 潘柏申, 郭玮()

复旦大学附属中山医院检验科,上海 200032

收稿日期:2018-11-19 出版日期:2019-10-30 发布日期:2019-11-01
作者简介:null
作者简介：曹旻璐,女,1991年生,学士,技师,主要从事分子诊断和基因检测工作。
基金资助:
国家自然科学基金面上项目（81572064）;国家自然科学基金面上项目（81772263）;国家自然科学基金面上项目（81972000）;国家自然科学基金青年项目（81902139）;上海市科学技术委员会基金项目（16411952100）;上海市卫生计生系统重要薄弱学科建设项目（2015ZB0201）;复旦大学附属中山医院临床研究专项基金项目（2018ZSLC05）;复旦大学附属中山医院创新基金项目（2018ZSCX13）

Performance comparison of the detection of circulating tumor cells in hepatocellular carcinoma patients by qRT-PCR platform and CellSearch system

CAO Minlu, SHEN Minna, ZHOU Yan, WANG Beili, ZHANG Chunyan, PAN Baishen, GUO Wei()

Department of Clinical Laboratory,Zhongshan Hospital,Fudan University,Shanghai 200032,China

Received:2018-11-19 Online:2019-10-30 Published:2019-11-01

摘要/Abstract

摘要： 目的探讨CellSearch系统与单标志物[上皮细胞黏附分子（EpCAM）]实时定量聚合酶链反应（qRT-PCR）平台、多标志物[EpCAM、CD133、CD90、细胞角蛋白（CK19）]qRT-PCR平台检测肝细胞肝癌（HCC）患者外周血循环肿瘤细胞（CTC）的阳性率与相关性。方法分别采用CellSearch系统、单标志物qRT-PCR平台和多标志物qRT-PCR平台检测32例HCC患者外周血CTC并计算阳性率。采用Spearman相关分析评估各方法间的相关性。结果单标志物（EpCAM）qRT-PCR平台检测CTC的阳性率为46.9%（15/32）,多标志物（EpCAM、CD133、CD90、CK19）qRT-PCR平台检测CTC的阳性率为65.6%（21/32）;CellSearch系统检测CTC的阳性率为28.1%（9/32）。单标志物qRT-PCR平台与CellSearch系统的阳性符合率为75.0%（24/32,P=0.002）,多标志物qRT-PCR平台与CellSearch系统的阳性符合率为56.3%（18/32,P=0.034）,单标志物qRT-PCR平台与多标志物qRT-PCR平台的阳性符合率为81.3%（26/32,P=0.000）。采用多标志物qRT-PCR平台检测CTC时,不同患者4项标志物所占百分比各不相同,有明显异质性。结论多标志物qRT-PCR平台能明显提高HCC患者外周血CTC的阳性检出率,可更直观地反映肿瘤的异质性,适用于多样化的检测需求。

关键词: 实时定量聚合酶链反应, CellSearch系统, 循环肿瘤细胞, 肝癌, 标志物, 异质性

Abstract: Objective To compare the positive rates and correlation of CellSearch system and real-time quantitation polymerase chain reaction（qRT-PCR） platform in the detection of circulating tumor cells（CTC） in single-marker-[epithelial cell adhesion molecule（EpCAM）] and multi-marker-[EpCAM,CD133,CD90 and cytokeratin 19（CK19）] labeled patterns among hepatocellular carcinoma（HCC） patients. Methods The peripheral blood samples of 32 HCC patients were collected,and CTC were detected by CellSearch system and qRT-PCR platform（single-marker and multi-marker）. The positive rates and correlation were analyzed using Spearman correlation analysis. Results The positive rate of CTC detection by single-marker（EpCAM） qRT-PCR platform was 46.9%（15/32）,and that by multi-marker（EpCAM,CD133,CD90 and CK19） was 65.6%（21/32）. The positive rate of CTC detection by CellSearch system was 28.1%（9/32）. The consistency of positive rate between single-marker qRT-PCR platform and CellSearch system was 75.0%（24/32,P=0.002）,that between multi-marker qRT-PCR platform and CellSearch system was 56.3%（18/32,P=0.034）,and that between single-marker and multi-marker qRT-PCR platform was 81.3%（26/32,P=0.000）. When using the qRT-PCR platform for multi-marker,the percentages of the 4 markers varied,and there existed obvious heterogeneity. Conclusions The multi-marker qRT-PCR platform can improve the positive rate of peripheral blood CTC detection in HCC patients,which directly reflects tumor heterogeneity and fits diverse detection demands.

Key words: Real-time quantitation polymerase chain reaction, CellSearch system, Circulating tumor cell, Hepatocellular carcinoma, Marker, Heterogeneity

中图分类号:

R446.1

曹旻璐, 沈敏娜, 周琰, 王蓓丽, 张春燕, 潘柏申, 郭玮. qRT-PCR平台和CellSearch系统检测肝细胞肝癌患者循环肿瘤细胞性能比较[J]. 检验医学, 2019, 34(10): 927-931.

CAO Minlu, SHEN Minna, ZHOU Yan, WANG Beili, ZHANG Chunyan, PAN Baishen, GUO Wei. Performance comparison of the detection of circulating tumor cells in hepatocellular carcinoma patients by qRT-PCR platform and CellSearch system[J]. Laboratory Medicine, 2019, 34(10): 927-931.

图/表 3

参考文献 15

[1]	SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2015[J]. CA Cancer J Clin,2015,65(1):5-29.
[2]	RAHBARI N N,MEHRABI A,MOLLBERG N M,et al.Hepatocellular carcinoma:current management and perspectives for the future[J]. Ann Surg,2011,253(3):453-469.
[3]	PLAKS V,KOOPMAN C D,WERB Z.Cancer. Circulating tumor cells[J]. Science,2013,341(6151):1186-1188.
[4]	ALIX-PANABIÈRES C,PANTEL K. Technologies for detection of circulating tumor cells:facts and vision[J]. Lab Chip,2014,14(1):57-62.
[5]	OZKUMUR E,SHAH A M,CICILIANO J C,et al. Inertial focusing for tumor antigen-dependent and independent sorting of rare circulating tumor cells[J]. Sci Transl Med,2013,5(179):179ra47.
[6]	GUO W,YANG X R,SUN Y F,et al.Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellualr carcinoma by an optimized negative enrichment and qRT-PCR-based platform[J]. Clin Cancer Res,2014,20(18):4794-4805.
[7]	SUN Y F,XU Y,YANG X R,et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology,2013,57(4):1458-1468.
[8]	REINHOLZ M M,KITZMANN K A,TENNER K,et al.Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials,N0234/336/436/437[J]. Clin Cancer Res,2011,17(22):7183-7193.
[9]	GUO W,SUN Y F,SHEN M N,et al.Circulating tumor cells with stem-like phenotypes for diagnosis,prognosis,and therapeutic response evaluation in hepatocellular carcinoma[J]. Clin Cancer Res,2018,24(9):2203-2213.
[10]	FORNER A,LLOVET J M,BRUIX J.Hepatocellular carcinoma[J]. Lancet,2012,379(9822):1245-1255.
[11]	MA S,TANG K H,CHAN Y P,et al.miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced unclear protein 1[J]. Cell Stem Cell,2010,7(6):694-707.
[12]	YANG Z F,HO D W,NG M N,et al.Significance of CD90+ cancer stem cells in human liver cancer[J]. Cancer cell,2008,13(2):153-166.
[13]	YAMASHITA T,HONDA M,NAKAMOTO Y,et al.Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma[J]. Hepatology,2013,57(4):1484-1497.
[14]	GOVAERE O,KOMUTA M,BERKERS J,et al.Keratin 19:a key role player in the invasion of human hepatocellular carcinomas[J]. Gut,2014,63(4):674-685.
[15]	KELLEY R K,MAQBANUA M J,BUTLER T M,et al.Circulating tumor cells in hepatocellular carcinoma:a pilot study of detection,enumeration,and next-generation sequencing in cases and controls[J]. BMC Cancer,2015,15:206.

qRT-PCR平台和CellSearch系统检测肝细胞肝癌患者循环肿瘤细胞性能比较

Performance comparison of the detection of circulating tumor cells in hepatocellular carcinoma patients by qRT-PCR platform and CellSearch system

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 15

相关文章 15

编辑推荐

Metrics

[1]	周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811.
[2]	卫明珠, 潘继文, 罗锐, 陈俊辉. 凝血4项和肿瘤标志物对乙型肝炎相关肝癌的辅助诊断价值[J]. 检验医学, 2023, 38(9): 901-904.
[3]	孙泽朋, 王洪彬, 王建东, 宋德伟, 肖鹏. 心肌损伤多肽和蛋白类标志物方法学分析和进展[J]. 检验医学, 2023, 38(8): 784-789.
[4]	中国康复医学会医学检验与康复专业委员会, 上海市医学会分子诊断专科分会, 上海市免疫学会肿瘤免疫分会, 上海中医药大学附属岳阳中西医结合医院, 上海市临床检验中心, 中国中西医结合学会检验医学专业委员会, 上海市抗癌协会检验医学专业委员会, 上海市抗癌协会肿瘤标志物专业委员会. 肝癌三项（AFP、AFP-L3%、DCP）与GALAD、类GALAD模型临床应用专家共识[J]. 检验医学, 2023, 38(7): 607-623.
[5]	陈文举, 周勇, 徐佳佳, 王攀. 血清外泌体miR-23b-3p和miR-4429诊断HCC的价值[J]. 检验医学, 2023, 38(7): 624-628.
[6]	张欣, 马丽娟. 儿童心脏标志物检测的临床意义[J]. 检验医学, 2023, 38(6): 505-509.
[7]	张敏, 王彬宇, 迟伟群, 刘禹. 外泌体非编码RNA作为疾病诊断生物标志物的研究进展[J]. 检验医学, 2023, 38(6): 594-598.
[8]	高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306.
[9]	陈慧, 陈光辉, 梁映亮, 王万党, 尹志军. 基于GEO数据库筛选妊娠糖尿病关键基因及其诊断价值分析[J]. 检验医学, 2023, 38(3): 276-281.
[10]	吴炯, 胡嘉华, 施美芳, 刘涛, 戴洁, 卢忻怡, 邹政. 前列腺癌生物标志物研究进展[J]. 检验医学, 2023, 38(2): 190-195.
[11]	刘庆阳, 袁建明, 夏进军, 姜风英, 王秋波, 王晓明. 基于GEO数据库和临床样本验证CXCL9作为类风湿关节炎生物标志物的研究[J]. 检验医学, 2023, 38(12): 1121-1129.
[12]	周福荣, 李龑杼, 刘勇敢. lncRNA SNP在结直肠癌易感性预测和预后评估中的应用[J]. 检验医学, 2023, 38(12): 1206-1210.
[13]	鲁启源, 卢建华. 人工关节假体周围感染诊断生物标志物研究进展[J]. 检验医学, 2023, 38(10): 997-1002.
[14]	陈雪薇, 李一荣. 基于GEO数据库筛选代谢综合征潜在生物标志物[J]. 检验医学, 2023, 38(1): 32-38.
[15]	吴亚婷, 李卓林, 雷艳, 贾如雪, 张胜行, 王水良. 尿液中miRNA作为常见恶性肿瘤生物标志物研究进展[J]. 检验医学, 2023, 38(1): 94-99.